Pradaxa and Risk of Heart Attack
Significant linkages have been made between Pradaxa and massive internal bleeding but new studies now suggest an increased risk of heart attack for patients of Pradaxa. According to WebMD, when compared to Warfarin and placebos, Pradaxa poses a 33% increased risk of heart attack. A report published in the Archives of Internal Medicine concluded the following, "Dabigatran [Pradaxa] is associated with an increased risk of MI or ACS in a broad spectrum of patients when tested against different controls. Clinicians should consider the potential of these serious harmful cardiovascular effects with use of dabigatran."
Some medical professionals maintain that the benefits of Pradaxa (which aims to prevent stroke in atrial fibrillation patients) still outweighs the risks. That may be possible. The relatively small increase in risk of a heart attack may still be a risk worth taking, all else equal, but if the patient is already at risk of heart attack (or heart disease), the compounding effect can become quite dangerous.
Boehringer Ingelheim, the manufacturer of Pradaxa disagrees with the findings but naturally they have a massive financial incentive for the results to lean one way over the other. Only independent studies should be considered in this and similar circumstances.
Could these incentives have enticed Boehringer to release Pradaxa to the market without fully disclosing the serious side effects of their drug? Were they negligent in properly and thoroughly testing Pradaxa? If there negligence was in anyway responsible for the death or injury of Pradaxa patients, it is critical that they be held responsible.
PradaxaLaw would like to hear from any patients (or immediate family) where Pradaxa may have been administered and severe internal bleeding, or heart attack, or death have occurred. We have the resources to immediately start researching whether Pradaxa was responsible. We will do our best to provide adequate compensation to help ease any burdens that Pradaxa may have caused to you and your family. And we will do everything possible to disincentivize drug manufacturers from rushing their products to market before every measure possible has been taken to protect the health and safety of those taking these medications.
Some medical professionals maintain that the benefits of Pradaxa (which aims to prevent stroke in atrial fibrillation patients) still outweighs the risks. That may be possible. The relatively small increase in risk of a heart attack may still be a risk worth taking, all else equal, but if the patient is already at risk of heart attack (or heart disease), the compounding effect can become quite dangerous.
Boehringer Ingelheim, the manufacturer of Pradaxa disagrees with the findings but naturally they have a massive financial incentive for the results to lean one way over the other. Only independent studies should be considered in this and similar circumstances.
Could these incentives have enticed Boehringer to release Pradaxa to the market without fully disclosing the serious side effects of their drug? Were they negligent in properly and thoroughly testing Pradaxa? If there negligence was in anyway responsible for the death or injury of Pradaxa patients, it is critical that they be held responsible.
PradaxaLaw would like to hear from any patients (or immediate family) where Pradaxa may have been administered and severe internal bleeding, or heart attack, or death have occurred. We have the resources to immediately start researching whether Pradaxa was responsible. We will do our best to provide adequate compensation to help ease any burdens that Pradaxa may have caused to you and your family. And we will do everything possible to disincentivize drug manufacturers from rushing their products to market before every measure possible has been taken to protect the health and safety of those taking these medications.